(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are ONWARD MEDICAL, NORTHERN DRILLING, and POXEL.

Financial Asset	Price	Change	Updated (EST)
ONWARD MEDICAL (ONWD.BR)	6.24	28.93%	2024-03-11 12:21:04
NORTHERN DRILLING (NODL.OL)	0.44	18.65%	2024-03-11 12:41:36
POXEL (POXEL.PA)	0.48	14.97%	2024-03-11 13:21:38
VIVORYON (VVY.AS)	0.58	14.29%	2024-03-11 12:04:30
TERACT (TRACT.PA)	0.59	13.9%	2024-03-11 13:23:42
XXL (XXL.OL)	0.82	8.71%	2024-03-11 12:44:32
MYHOTELMATCH (MHM.PA)	0.79	7.93%	2024-03-11 13:20:29
SMCP (SMCP.PA)	2.37	7.73%	2024-03-11 13:22:53
MAAT PHARMA (MAAT.PA)	8.76	6.83%	2024-03-11 13:07:43
GPE GROUP PIZZORNO (GPE.PA)	72.60	6.76%	2024-03-11 13:05:02

The three biggest losers today are REDITUS,SGPS, ATLANTIC SAPPHIRE, and SCHEERD.V KERCHOVE.

Financial Asset	Price	Change	Updated (EST)
REDITUS,SGPS (RED.LS)	0.06	-14.29%	2024-03-11 12:23:54
ATLANTIC SAPPHIRE (ASA.OL)	0.96	-10.28%	2024-03-11 12:24:54
SCHEERD.V KERCHOVE (SCHD.BR)	346.00	-9.9%	2024-03-11 12:21:26
DEEZER (DEEZR.PA)	2.04	-8.93%	2024-03-11 13:02:29
PCI BIOTECH HOLD (PCIB.OL)	1.55	-8.59%	2024-03-11 12:42:10
JINHUI SHIPP TRANS (JIN.OL)	5.80	-8.52%	2024-03-11 12:40:41
AFFLUENT MEDICAL (AFME.PA)	1.52	-8.18%	2024-03-11 12:45:14
MEMSCAP REGPT (MEMS.PA)	9.06	-7.93%	2024-03-11 13:20:13
BE SEMICONDUCTOR (BESI.AS)	138.10	-7.53%	2024-03-11 12:00:51
LAVIDE HOLDING (LVIDE.AS)	0.28	-6.71%	2024-03-11 12:02:45

Winners today

1. ONWARD MEDICAL (ONWD.BR)

28.93% Price Change

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

BEL 20 ended the session with ONWARD MEDICAL jumping 28.93% to €6.24 on Monday, after four successive sessions in a row of losses. BEL 20 rose 0.21% to €3,741.71, after three sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.93%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL’s stock is considered to be overbought (>=80).

More news about ONWARD MEDICAL.

2. NORTHERN DRILLING (NODL.OL)

18.65% Price Change

Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING rising 18.65% to €0.44 on Monday while Oslo Børs Benchmark Index_GI dropped 0.91% to €1,267.61.

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-5.88.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.

Yearly Top and Bottom Value

NORTHERN DRILLING’s stock is valued at kr0.44 at 21:40 EST, way under its 52-week high of kr33.90 and way above its 52-week low of kr0.31.

More news about NORTHERN DRILLING.

3. POXEL (POXEL.PA)

14.97% Price Change

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

CAC 40 ended the session with POXEL jumping 14.97% to €0.48 on Monday, after four sequential sessions in a row of losses. CAC 40 dropped 0.1% to €8,019.73, after three sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, POXEL has a trailing twelve months EPS of €-1.08.

More news about POXEL.

4. VIVORYON (VVY.AS)

14.29% Price Change

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

AEX-Index ended the session with VIVORYON rising 14.29% to €0.58 on Monday, after five sequential sessions in a row of losses. AEX-Index dropped 1.12% to €852.32, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.

Volatility

VIVORYON’s last week, last month’s, and last quarter’s current intraday variation average was a negative 12.05%, a negative 2.96%, and a positive 2.86%.

VIVORYON’s highest amplitude of average volatility was 12.05% (last week), 3.89% (last month), and 2.86% (last quarter).

More news about VIVORYON.

5. TERACT (TRACT.PA)

13.9% Price Change

Teract S.A. operates in retail business in Europe. The company operates through Garden Centre Retailer and Marketer segments. It operates garden centers and pet care shops under the Jardiland, Gamm vert, Delbard, and Jardinerie du Terroir brand names. The company also operates in the fresh, local, and organic produce sector under Frais d'Ici and Bio&Co brands with food outlets. It operates 1,597 stores. The company is based in Paris, France.

CAC 40 ended the session with TERACT rising 13.9% to €0.59 on Monday while CAC 40 fell 0.1% to €8,019.73.

Earnings Per Share

As for profitability, TERACT has a trailing twelve months EPS of €0.62.

PE Ratio

TERACT has a trailing twelve months price to earnings ratio of 0.95. Meaning, the purchaser of the share is investing €0.95 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.98%.

More news about TERACT.

6. XXL (XXL.OL)

8.71% Price Change

XXL ASA operates as a sports retailer. It offers sports equipment and sportswear for various sports, including running, football, golf, water sports, racket sports, and ice hockey; and fitness equipment, including treadmills and rowing machines, as well as food supplements and nutrition. The company also provides clothes for men, women, and children for baselayers, outerwear, casual wear, sportswear, and swimwear, as well as lifestyle shoes and winter shoes; outdoor and hunting products for fishing, wilderness living, and camping, such as tents, lavvos, sleeping bags, backpacks, cooking equipment as well as climbing gear; and hunting products, including firearms and ammunition, clothes, binoculars, optics, knives, and axes. In addition, it offers skis and ski accessories, such as shoes, poles, clothes, and other equipment for cross-country and downhill skiing, as well as snowboarding; high-end and everyday bikes comprising hybrid bikes, mountain bikes, city bikes, and electric bikes for children, women, and men; and bike equipment, such as helmets, shoes, spare parts, and clothes. Further, the company provides products that connect technology and sports/outdoor activities, including sport watches, action cameras, drones, GPS, earplugs and headphones, portable loudspeakers, sunglasses, pulse meters, power banks, and cycle computers. It operates stores in Norway, Sweden, and Finland, as well as e-commerce websites, such as xxl.no, xxl.se, xxl.fi, and xxl.dk. The company was founded in 2000 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with XXL rising 8.71% to €0.82 on Monday, after four successive sessions in a row of losses. Oslo Børs Benchmark Index_GI fell 0.91% to €1,267.61, after two consecutive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, XXL has a trailing twelve months EPS of kr-2.35.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.25%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 9.5%, now sitting on 7.96B for the twelve trailing months.

Moving Average

XXL’s worth is way under its 50-day moving average of kr1.02 and way below its 200-day moving average of kr1.03.

Volume

Today’s last reported volume for XXL is 2052730 which is 30.48% below its average volume of 2952920.

More news about XXL.

7. MYHOTELMATCH (MHM.PA)

7.93% Price Change

MyHotelMatch S.A. engages in the development of an online hotel reservation platform based on Artificial Intelligence (AI). It operates as an online travel agency based on the principle of online dating. MyHotelMatch S.A. was incorporated in 2010 and is headquartered in Biot, France.

CAC 40 ended the session with MYHOTELMATCH jumping 7.93% to €0.79 on Monday, following the last session’s downward trend. CAC 40 dropped 0.1% to €8,019.73, after three successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, MYHOTELMATCH has a trailing twelve months EPS of €-1.16.

Volatility

MYHOTELMATCH’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.31%, a negative 0.63%, and a positive 3.69%.

MYHOTELMATCH’s highest amplitude of average volatility was 4.87% (last week), 3.70% (last month), and 3.69% (last quarter).

Yearly Top and Bottom Value

MYHOTELMATCH’s stock is valued at €0.79 at 21:40 EST, way below its 52-week high of €3.88 and way above its 52-week low of €0.64.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MYHOTELMATCH’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for MYHOTELMATCH is 12540 which is 18.87% below its average volume of 15457.

More news about MYHOTELMATCH.

8. SMCP (SMCP.PA)

7.73% Price Change

SMCP S.A. operates as a ready-to-wear and accessories retail company in France and internationally. It offers women's wear, including dresses, trousers, skirts, shorts, t-shirts, pullovers, cardigans, bags, and footwear, as well as accessories; and men's wear, such as blazers, jackets, trench coats, leatherwear, suits, tuxedos, trousers, shorts, shirts, jeans, t-shirts, polo shirts, pullovers, and cardigans, as well as footwear, bags, ties, gloves, and hats. The company sells its products through a network of points of sale, stores, and websites, as well as corners in department stores under the Sandro, Maje, Claudie Pierlot, and Fursac brand names. SMCP S.A. was founded in 1984 and is headquartered in Paris, France.

CAC 40 ended the session with SMCP jumping 7.73% to €2.37 on Monday while CAC 40 fell 0.1% to €8,019.73.

Earnings Per Share

As for profitability, SMCP has a trailing twelve months EPS of €0.15.

PE Ratio

SMCP has a trailing twelve months price to earnings ratio of 15.8. Meaning, the purchaser of the share is investing €15.8 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.95%.

Moving Average

SMCP’s value is way under its 50-day moving average of €2.92 and way under its 200-day moving average of €4.83.

Yearly Top and Bottom Value

SMCP’s stock is valued at €2.37 at 21:40 EST, below its 52-week low of €2.37.

Volatility

SMCP’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.07%, a negative 0.89%, and a positive 2.67%.

SMCP’s highest amplitude of average volatility was 3.47% (last week), 3.14% (last month), and 2.67% (last quarter).

Volume

Today’s last reported volume for SMCP is 298106 which is 70.77% above its average volume of 174559.

More news about SMCP.

9. MAAT PHARMA (MAAT.PA)

6.83% Price Change

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

CAC 40 ended the session with MAAT PHARMA jumping 6.83% to €8.76 on Monday, following the last session’s downward trend. CAC 40 fell 0.1% to €8,019.73, after three sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, MAAT PHARMA has a trailing twelve months EPS of €-1.4.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.11%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 178.9%, now sitting on 2.31M for the twelve trailing months.

More news about MAAT PHARMA.

10. GPE GROUP PIZZORNO (GPE.PA)

6.76% Price Change

Groupe Pizzorno Environnement provides environmental services primarily in France. It engages in the waste treatment; production and recycling of secondary raw materials, such as paper, metals, plastics, and glass; development of technologies and services for the recovery of bio-waste; production of heat and electricity from waste treatment; and collection of household waste, as well as offers cleanliness services. The company was founded in 1974 and is based in Draguignan, France.

CAC 40 ended the session with GPE GROUP PIZZORNO jumping 6.76% to €72.60 on Monday, after four consecutive sessions in a row of gains. CAC 40 slid 0.1% to €8,019.73, after three successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, GPE GROUP PIZZORNO has a trailing twelve months EPS of €4.88.

PE Ratio

GPE GROUP PIZZORNO has a trailing twelve months price to earnings ratio of 14.88. Meaning, the purchaser of the share is investing €14.88 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.41%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10.5%, now sitting on 226.87M for the twelve trailing months.

Moving Average

GPE GROUP PIZZORNO’s worth is way above its 50-day moving average of €56.78 and way higher than its 200-day moving average of €50.89.

Yearly Top and Bottom Value

GPE GROUP PIZZORNO’s stock is valued at €72.60 at 21:40 EST, way higher than its 52-week high of €61.00.

More news about GPE GROUP PIZZORNO.

Losers Today

1. REDITUS,SGPS (RED.LS)

-14.29% Price Change

Reditus, Sociedade Gestora de Participações Sociais, S.A., through its subsidiaries, provides business process outsourcing, IT outsourcing, and IT consulting services in Portugal and internationally. The company offers client services, including client, financial, human resource, doc, and facilities management, as well as other business process services; and IT infrastructure services and solutions in the areas of advisory, design, installation, and maintenance of systems and solutions, storage, network, and security. It also provides specialized outsourcing services in the areas of application development and maintenance, DBs and system administration, business intelligence and applications, telecom engineering and networks, and support and helpdesk; and information security services and solutions, as well as security managed services. In addition, the company offers enterprise content management services, solutions, and products for deployment of projects in scanning, document management, and workflow in multi-channel topologies; lean management services and solutions in practical application of diagnostic methodologies; and management and IT consulting services and solutions. Further, it is involved in the development, management, and maintenance of software applications and analytical solutions; and provision of cooperation and development services and solutions in the areas of corporate procurement, project management, and economic and social development, as well as training and personal development services. The company serves public, health, telecom, media, utilities, financial services, consumer, retail, and transportation sectors. The company was founded in 1966 and is headquartered in Lisbon, Portugal.

PSI ended the session with REDITUS,SGPS dropping 14.29% to €0.06 on Monday, following the last session’s downward trend. PSI rose 0.05% to €6,158.39, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, REDITUS,SGPS has a trailing twelve months EPS of €0.18.

PE Ratio

REDITUS,SGPS has a trailing twelve months price to earnings ratio of 0.33. Meaning, the purchaser of the share is investing €0.33 for every euro of annual earnings.

Yearly Top and Bottom Value

REDITUS,SGPS’s stock is valued at €0.06 at 21:40 EST, way above its 52-week high of €0.04.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 23.77M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, REDITUS,SGPS’s stock is considered to be oversold (<=20).

More news about REDITUS,SGPS.

2. ATLANTIC SAPPHIRE (ASA.OL)

-10.28% Price Change

Atlantic Sapphire ASA, together with its subsidiaries, engages in the land-based salmon farming business. It operates through two segments, Fish Farming (Denmark); and Fish Farming (US). The company is involved in the production and sale of salmon. It operates in the United States, Denmark, and internationally. The company was founded in 2010 and is headquartered in Vikebukt, Norway.

Oslo Børs Benchmark Index_GI ended the session with ATLANTIC SAPPHIRE sliding 10.28% to €0.96 on Monday while Oslo Børs Benchmark Index_GI fell 0.91% to €1,267.61.

Earnings Per Share

As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-5.09.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

More news about ATLANTIC SAPPHIRE.

3. SCHEERD.V KERCHOVE (SCHD.BR)

-9.9% Price Change

Scheerders van Kerchove's Verenigde fabrieken nv manufactures and distributes building materials. It offers façade panels, slates, facing bricks, and corrugated sheets. The company was founded in 1905 and is based in Sint-Niklaas, Belgium.

BEL 20 ended the session with SCHEERD.V KERCHOVE dropping 9.9% to €346.00 on Monday, after five sequential sessions in a row of losses. BEL 20 jumped 0.21% to €3,741.71, after three sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, SCHEERD.V KERCHOVE has a trailing twelve months EPS of €-2.15.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.06%.

Volume

Today’s last reported volume for SCHEERD.V KERCHOVE is 5 which is 16.66% below its average volume of 6.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.1%, now sitting on 39.97M for the twelve trailing months.

Yearly Top and Bottom Value

SCHEERD.V KERCHOVE’s stock is valued at €346.00 at 21:40 EST, under its 52-week low of €380.00.

Moving Average

SCHEERD.V KERCHOVE’s worth is way under its 50-day moving average of €429.24 and way below its 200-day moving average of €464.83.

More news about SCHEERD.V KERCHOVE.

4. DEEZER (DEEZR.PA)

-8.93% Price Change

Deezer S.A. provides music streaming services worldwide. The company streams songs, audio books, podcast, and radio channels. It offers its music steaming services through website, Deezer.com and other wireless audio systems; and operates in approximately 180 countries. The company is based in Paris, France.

CAC 40 ended the session with DEEZER sliding 8.93% to €2.04 on Monday while CAC 40 slid 0.1% to €8,019.73.

Earnings Per Share

As for profitability, DEEZER has a trailing twelve months EPS of €-0.47.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 484.66M for the twelve trailing months.

More news about DEEZER.

5. PCI BIOTECH HOLD (PCIB.OL)

-8.59% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD dropping 8.59% to €1.55 on Monday while Oslo Børs Benchmark Index_GI slid 0.91% to €1,267.61.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.

Volume

Today’s last reported volume for PCI BIOTECH HOLD is 153399 which is 26.37% below its average volume of 208353.

Yearly Top and Bottom Value

PCI BIOTECH HOLD’s stock is valued at kr1.55 at 21:40 EST, way below its 52-week high of kr3.40 and way higher than its 52-week low of kr1.20.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.4%, now sitting on 2.99M for the twelve trailing months.

Moving Average

PCI BIOTECH HOLD’s value is way under its 50-day moving average of kr2.03 and way under its 200-day moving average of kr1.98.

More news about PCI BIOTECH HOLD.

6. JINHUI SHIPP TRANS (JIN.OL)

-8.52% Price Change

Jinhui Shipping and Transportation Limited, an investment holding company, engages in ship chartering and owning activities internationally. The company provides ship management and shipping agent services, as well as engages in the money lending and property investment activities. It also owns a fleet of twenty four grabs fitted supramaxes and one chartered-in-panamax. The company was founded in 1987 and is based in Hong Kong, Hong Kong. Jinhui Shipping and Transportation Limited operates as a subsidiary of Jinhui Holdings Company Limited.

Oslo Børs Benchmark Index_GI ended the session with JINHUI SHIPP TRANS sliding 8.52% to €5.80 on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI dropped 0.91% to €1,267.61, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, JINHUI SHIPP TRANS has a trailing twelve months EPS of kr-7.12.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.47%.

Volume

Today’s last reported volume for JINHUI SHIPP TRANS is 90824 which is 1.55% above its average volume of 89435.

Revenue Growth

Year-on-year quarterly revenue growth declined by 16.9%, now sitting on 81.87M for the twelve trailing months.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on May 25, 2023, the estimated forward annual dividend rate is 0.84 and the estimated forward annual dividend yield is 13.25%.

More news about JINHUI SHIPP TRANS.

7. AFFLUENT MEDICAL (AFME.PA)

-8.18% Price Change

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

CAC 40 ended the session with AFFLUENT MEDICAL falling 8.18% to €1.52 on Monday while CAC 40 fell 0.1% to €8,019.73.

Earnings Per Share

As for profitability, AFFLUENT MEDICAL has a trailing twelve months EPS of €-0.65.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.37%.

Volatility

AFFLUENT MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was 1.43%, 0.33%, and 4.36%.

AFFLUENT MEDICAL’s highest amplitude of average volatility was 2.75% (last week), 5.06% (last month), and 4.36% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 16.3%, now sitting on 1.22M for the twelve trailing months.

Moving Average

AFFLUENT MEDICAL’s value is way above its 50-day moving average of €1.31 and way higher than its 200-day moving average of €1.23.

Yearly Top and Bottom Value

AFFLUENT MEDICAL’s stock is valued at €1.52 at 21:40 EST, way below its 52-week high of €2.30 and way above its 52-week low of €0.93.

More news about AFFLUENT MEDICAL.

8. MEMSCAP REGPT (MEMS.PA)

-7.93% Price Change

MEMSCAP, S.A. provides micro-electro-mechanical systems (MEMS) based solutions for aerospace and defense, optical communications, medical, and biomedical markets worldwide. The company offers pressure sensors, pressure transducers, and pressure switches for various applications, such as air data computers, cabin pressure, engine control, altimeters, barometers, cockpit instruments, and air data test sets. It also provides gold coated and titanium-based pressure transducers, plastic domes, line-sets, and related accessories. In addition, the company supplies optical MEMS chips for variable optical attenuators in optical telecommunication markets; and provides the multi-user MEMS processes. Further, it offers mounting brackets, snap holders, non-sterile and sterile domes, and monitoring line sets. MEMSCAP, S.A. was founded in 1997 and is based in Crolles, France.

CAC 40 ended the session with MEMSCAP REGPT dropping 7.93% to €9.06 on Monday, after four sequential sessions in a row of gains. CAC 40 slid 0.1% to €8,019.73, after three sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, MEMSCAP REGPT has a trailing twelve months EPS of €0.16.

PE Ratio

MEMSCAP REGPT has a trailing twelve months price to earnings ratio of 56.63. Meaning, the purchaser of the share is investing €56.63 for every euro of annual earnings.

Volatility

MEMSCAP REGPT’s last week, last month’s, and last quarter’s current intraday variation average was 2.26%, 1.18%, and 2.94%.

MEMSCAP REGPT’s highest amplitude of average volatility was 2.26% (last week), 2.23% (last month), and 2.94% (last quarter).

More news about MEMSCAP REGPT.

9. BE SEMICONDUCTOR (BESI.AS)

-7.53% Price Change

BE Semiconductor Industries N.V. engages in the development, manufacture, marketing, sale, and service of semiconductor assembly equipment for the semiconductor and electronics industries worldwide. The company's principal products include die attach equipment, such as single chip, multi-chip, multi module, flip chip, thermal compression bonding, fan out wafer level packaging, hybrid and embedded bridge die bonding, and die sorting systems; and packaging equipment, including conventional, ultra-thin, and wafer level molding, as well as trim and form, and singulation systems. Its principal products also comprise plating equipment, such as tin, copper, and precious metal and solar plating systems, as well as related process chemicals; and tooling, conversion kits, spare parts, and other services. The company's principal brand names include Datacon, Esec, Fico, and Meco. It offers its products primarily to multinational chip manufacturers, assembly subcontractors, and electronics and industrial companies. The company was incorporated in 1995 and is headquartered in Duiven, the Netherlands.

AEX-Index ended the session with BE SEMICONDUCTOR falling 7.53% to €138.10 on Monday, following the last session’s downward trend. AEX-Index fell 1.12% to €852.32, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, BE SEMICONDUCTOR has a trailing twelve months EPS of €2.23.

PE Ratio

BE SEMICONDUCTOR has a trailing twelve months price to earnings ratio of 61.93. Meaning, the purchaser of the share is investing €61.93 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.73%.

More news about BE SEMICONDUCTOR.

10. LAVIDE HOLDING (LVIDE.AS)

-6.71% Price Change

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. is based in Amsterdam, the Netherlands.

AEX-Index ended the session with LAVIDE HOLDING falling 6.71% to €0.28 on Monday while AEX-Index slid 1.12% to €852.32.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.02.

Volume

Today’s last reported volume for LAVIDE HOLDING is 14991 which is 21.41% below its average volume of 19076.

More news about LAVIDE HOLDING.

Stay up to date with our winners and losers daily report